COVID-19 resources

Since the COVID-19 outbreak, 3M has doubled its global output of N95 respirators to an annual rate of more than 1.1 billion per year, or nearly 100 million per month. See how we’re supporting healthcare workers in the U.S. and around the globe through this pandemic.

3M introduces hotline, releases price lists to help combat counterfeits, price gouging during COVID-19. Read the announcement here.

3M posted the following update on additional details about our capacity increase of N95 respirators, strong measures to combat price gouging and counterfeiting, and new partnerships to help protect our healthcare workers on the front lines.

During this global crisis, demand for personal protective equipment (PPE) continues to far exceed supply for the entire industry. We continue working with governments, health agencies, distributors and others to prioritize supplies to the most critical customer and public health needs.

As the novel coronavirus spread throughout China, it became clear that a key piece of protective equipment for healthcare workers was the N95 respirator mask.

Newly designed powered air-purifying respirators (PAPRs), developed by Ford in close collaboration with 3M, are on the way to healthcare workers fighting COVID-19.

To help the world respond to COVID-19, 3M and researchers at MIT are testing a new rapid test that detects the virus. Accelerated research is underway to learn if a simple-to-use, diagnostic device can produce highly accurate results within minutes and is feasible to mass manufacture.

3M’s Chairman and CEO Mike Roman joins Steve Clemons with The Hill to discuss the state of play on respirators today and what we need tomorrow; on what is good and what is not good about global supply chains and the nature of leadership in these stressed out times.

Garri Garrison sat down with Becker’s Healthcare to discuss her new role at 3M HIS, how hospitals can more easily connect with clinicians on the front end of the revenue cycle and audit teams on the back end, and the driving principles for revenue cycle in the future.

When the COVID-19 pandemic began, 3M plant managers were faced with the challenge of leading a team of dedicated frontline workers in an unprecedented situation. They had to determine how to safely operate, work together and move forward. 

3M scientists helping the world get back to outside: 3M biopharmaceutical purification technologies help advance vaccine and therapeutics research, development and manufacturing in the continued fight against COVID-19. 

During this global crisis, demand for personal protective equipment (PPE) continues to far exceed supply for the entire industry. We continue working with governments, health agencies, distributors and others to prioritize supplies to the most critical customer and public health needs.

Through global challenges of all kinds, 3M has partnered with governments and industry partners to help the world recover. The COVID-19 pandemic has been a pressure test of our system. It has taught us what happens when global supply chain, governments and the world’s health care system are stretched to their limits. In this report, 3M shares recommendations to identify the future challenges and how to develop public-private relationships to help solve them.

3M is committed to help combat fraudulent activity in connection with 3M products and the COVID-19 pandemic. As we continue to increase production of critically needed N95 respirators, 3M is working with law enforcement authorities around the world to stop counterfeiting and remove fake products from the market to protect frontline workers fighting COVID-19.

The vaccination clinic that hundreds of 3Mers attended, is just another way 3M is helping fight the COVID-19 pandemic. 3M encourages everyone to get vaccinated when they have access to a government-approved vaccine and is working to help employees and their communities find access to those vaccinations.

When 3M Aberdeen, South Dakota, got the call to ramp-up production of N95 respirators in January 2020 to help respond to the pandemic, the scale of the work ahead was massive. But by adding hundreds of people and expanding the plant and production lines, Aberdeen helped bring monthly production of N95 respirators to the U.S. to 95 million per month.